Caspase-3 activation as a key factor for HBx-transformed cell death

Area of Science:

• Hepatocellular Carcinoma Research
• Molecular Oncology
• Virology

Background:

• Hepatitis B virus X protein (HBx) is linked to hepatocellular carcinoma development.
• Nuclear factor-kappa B (NF-kappaB) activation is implicated in the growth of HBx-transformed cells.
• Identifying effective therapeutic targets for HBx-mediated cancers is crucial.

Purpose of the Study:

• To investigate potential therapeutic targets for HBx-mediated cancers.
• To evaluate the role of NF-kappaB and caspase activation in HBx-transformed cells.
• To identify agents that inhibit the proliferation of these cancer cells.

Main Methods:

• Chang/HBx cells expressing HBx were treated with inhibitors of NF-kappaB, proteasome, and DNA topoisomerase.
• Evaluated NF-kappaB activation, endoplasmic reticulum (ER)-stress, caspase-3 activation, and cell proliferation.
• Utilized specific inhibitors like wortmannin, LY294002, MG132, and camptothecin (CPT).

Main Results:

• NF-kappaB inhibition showed minimal impact on HBx-transformed cell survival and proliferation.
• Proteasome inhibitors (Pro1, MG132) enhanced ER-stress and caspase activation (caspase-12, -9, -3), reducing cell proliferation.
• Camptothecin (CPT) induced caspase-3 activation and reduced proliferation; this effect was reversible with a caspase-3 inhibitor.

Conclusions:

• Caspase-3 activation, rather than NF-kappaB inhibition, is a critical pathway for targeting HBx-transformed hepatocellular carcinoma.
• Proteasome inhibitors and CPT demonstrate potential as anticancer therapeutics by inducing apoptosis.
• Further research into caspase-3 regulators could lead to novel treatments for HBx-mediated cancers.